ARCHIVES

Higher Response For Gleevec In Trial; CML Patients Allowed To Switch

This article is from The Cancer Letter archive.

Vol. 25 No. 1 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Autologous BMT Equivalent To Allogeneic For Myeloma

December 31, 2010

NCI Needs 100 SBIR Contracts By April 1 To Avoid Losing $5 Million; NIH Objects To DCT Comments

March 22, 1985

CCIRC Considers Programs Involved with Including Multimodality Studies

October 10, 1975

NCCS Plans Rays Of Hope Event At Ellipse On Sept. 15.

July 27, 2001

Suit Against Craig Thompson Settled As Company He Co-Founded Licenses “Newly Identified” Discoveries From UPenn

September 14, 2012

Black Teens At Higher Risk Of Tobacco Addiction.

February 2, 2001